Centene (NYSE:CNC) issued an update on its FY20 earnings guidance on Monday morning. The company provided EPS guidance of $4.64 to $4.84 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.80. The company issued revenue guidance of $78.6-79.4 billion, compared to the consensus revenue estimate of $79.35 billion.Centene also updated its FY19 guidance to $4.29-4.49 EPS.
Shares of Centene stock opened at $64.78 on Thursday. The firm has a 50-day simple moving average of $61.55 and a two-hundred day simple moving average of $52.54. The company has a market cap of $26.14 billion, a P/E ratio of 18.30, a price-to-earnings-growth ratio of 0.92 and a beta of 0.91. Centene has a fifty-two week low of $41.62 and a fifty-two week high of $69.25. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.01.
Centene (NYSE:CNC) last issued its quarterly earnings data on Tuesday, October 22nd. The company reported $0.96 earnings per share for the quarter, topping analysts’ consensus estimates of $0.95 by $0.01. The business had revenue of $18.98 billion during the quarter, compared to the consensus estimate of $18.39 billion. Centene had a net margin of 1.87% and a return on equity of 15.54%. The company’s revenue was up 17.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.79 earnings per share. Equities research analysts forecast that Centene will post 4.42 EPS for the current year.
A number of research analysts have weighed in on CNC shares. BMO Capital Markets upped their price objective on shares of Centene from $65.00 to $70.00 and gave the stock an outperform rating in a research report on Monday, December 16th. Morgan Stanley decreased their price objective on shares of Centene from $64.00 to $62.00 and set an overweight rating for the company in a research report on Thursday, September 26th. Deutsche Bank decreased their price objective on shares of Centene from $62.00 to $60.00 and set a buy rating for the company in a research report on Wednesday, October 23rd. ValuEngine upgraded shares of Centene from a strong sell rating to a sell rating in a research report on Wednesday, October 2nd. Finally, Piper Jaffray Companies reiterated a buy rating and issued a $80.00 price objective on shares of Centene in a research report on Monday, December 16th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and eleven have issued a buy rating to the company’s stock. Centene presently has an average rating of Buy and an average price target of $71.31.
In related news, Director Tommy G. Thompson sold 500 shares of the company’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $62.98, for a total transaction of $31,490.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Keith H. Williamson sold 11,000 shares of the company’s stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $59.13, for a total transaction of $650,430.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 285,519 shares of company stock valued at $16,416,060. Insiders own 2.50% of the company’s stock.
Centene Corporation operates as a diversified and multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. The company's Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children's health insurance program, long-term services and support, foster care, and medicare-medicaid plans, which covers dually eligible individuals, as well as aged, blind, or disabled programs.
Receive News & Ratings for Centene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centene and related companies with MarketBeat.com's FREE daily email newsletter.